|
12 Jun 2019 |
Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
|
|
12 Jun 2019 |
OrthoTrophix Presents Clinical Data at European Congress of Rheumatology
|
|
12 Jun 2019 |
BioInvent publishes first clinical data from BI-1206 Phase l/lla trials
|
|
12 Jun 2019 |
Sobi acquires emapalumab and related assets
|
|
12 Jun 2019 |
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
|
|
12 Jun 2019 |
Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
|
|
12 Jun 2019 |
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
|
|
12 Jun 2019 |
New Subcutaneous Formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) Shows Positive Results for the Treatment of Rheumatoid Arthritis (RA) In Data Presented at the Annual European Congress of Rheumatology (EULAR 2019)
|
|
12 Jun 2019 |
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
|
|
12 Jun 2019 |
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
|
|
11 Jun 2019 |
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
|
|
11 Jun 2019 |
Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
|
|
11 Jun 2019 |
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
|
|
11 Jun 2019 |
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
|
|
11 Jun 2019 |
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
|
|
11 Jun 2019 |
BiomX Licenses Novel Targets for Liver Disease Phage Therapy Program From JSR Corporation in Japan
|
|
11 Jun 2019 |
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
|
|
10 Jun 2019 |
FDA Grants Genentech’s Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma
|
|
10 Jun 2019 |
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
|
|
10 Jun 2019 |
Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019
|
